|
AU3515497A
(en)
*
|
1996-07-29 |
1998-02-20 |
Warner-Lambert Company |
Improved process for the synthesis of protected esters of (s)-3,4-dihydroxybutyric acid
|
|
US6713290B2
(en)
|
1998-07-24 |
2004-03-30 |
Samsung Fine Chemicals Co., Ltd. |
Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
|
|
KR100332703B1
(ko)
*
|
1998-07-24 |
2002-08-27 |
삼성정밀화학 주식회사 |
광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
|
|
JP3614367B2
(ja)
*
|
1998-07-24 |
2005-01-26 |
サムスン ファイン ケミカルズ カンパニー リミテッド |
光学的に純粋な（ｓ）−３，４−ジヒドロキシ酪酸誘導体の連続的な製造方法
|
|
US6235930B1
(en)
*
|
1999-03-31 |
2001-05-22 |
Board Of Trustees Operating Michigan State University |
Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
|
|
HU227840B1
(en)
*
|
1999-05-06 |
2012-05-02 |
Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag |
Intermediates of atorvastatin synthesis and process for producing them
|
|
EP1237865B1
(en)
|
1999-12-17 |
2005-11-16 |
Pfizer Science and Technology Ireland Limited |
A factory scale process for producing crystalline atorvastatin trihydrate hemi calcium salt
|
|
ATE320415T1
(de)
|
1999-12-17 |
2006-04-15 |
Pfizer Science & Tech Ltd |
Verfahren zur herstellung von kristallin atorvastin kalcium
|
|
JP4598917B2
(ja)
*
|
2000-04-28 |
2010-12-15 |
ダイセル化学工業株式会社 |
ラクトンの製造方法
|
|
KR100645665B1
(ko)
|
2000-07-27 |
2006-11-13 |
에스케이 주식회사 |
(ｓ)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
|
|
EP1734034A3
(en)
|
2001-01-09 |
2007-01-03 |
Warner-Lambert Company LLC |
Carboxylic acid salts of beta-alanine esters or -amides
|
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
|
WO2002057229A1
(en)
*
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
|
SK16002003A3
(sk)
|
2001-06-29 |
2004-12-01 |
Warner-Lambert Company Llc |
Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín)
|
|
HUP0401014A2
(hu)
*
|
2001-07-06 |
2004-08-30 |
Teva Pharmaceutical Industries Ltd. |
Eljárás 7-amino-szin-3,5-dihidroxi-heptánsavszármazékok előállítására, 6-ciano-szin-3,5-dihidroxi-hexánsav származékokon keresztül
|
|
PT1478650E
(pt)
*
|
2002-02-25 |
2010-01-04 |
Biocon Ltd |
Novos ésteres boronato
|
|
GB0211716D0
(en)
|
2002-05-22 |
2002-07-03 |
Phoenix Chemicals Ltd |
Process
|
|
CA2494269A1
(en)
*
|
2002-08-06 |
2004-02-19 |
Warner-Lambert Company Llc |
Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
|
|
DE60226518D1
(de)
*
|
2002-09-18 |
2008-06-19 |
Sk Holdings Co Ltd |
Kontinuierliches verfahren zur herstellung von optisch reinem (s)-beta hydroxy- gamma-butyrolacton
|
|
AU2003263031A1
(en)
*
|
2002-09-20 |
2004-04-08 |
Diversa Corporation |
Chemoenzymatic methods for the synthesis of statins and stain intermediates
|
|
US6713639B1
(en)
|
2002-10-28 |
2004-03-30 |
Council Of Scientific And Industrial Research |
Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
|
|
JP2006523670A
(ja)
*
|
2003-04-14 |
2006-10-19 |
ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー |
５−（４−フルオロフェニル）−１−［２−（（２ｒ，４ｒ）−４−ヒドロキシ−６−オキソ−テトラヒドロ−ピラン−２−イル）エチル］−２−イソプロピル−４−フェニル−１ｈ−ピロール−３−カルボン酸フェニルアミドの調製方法
|
|
SI1631533T1
(sl)
*
|
2003-04-22 |
2009-08-31 |
Bicon Ltd |
Nov postopek za stereoselektivno redukcijo beta - ketoestrov
|
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
KR100781420B1
(ko)
*
|
2003-09-17 |
2007-12-03 |
워너-램버트 캄파니 엘엘씨 |
[Ｒ-(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-다이하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산의 결정성 형태
|
|
WO2005068642A2
(en)
|
2003-10-01 |
2005-07-28 |
Board Of Trustees Operating Michigan State University |
Bacterial synthesis of 1,2,4-butanetriol enantiomers
|
|
WO2005100313A1
(en)
*
|
2004-04-16 |
2005-10-27 |
Pfizer Products Inc. |
Process for forming amorphous atorvastatin calcium
|
|
US7875731B2
(en)
|
2004-05-05 |
2011-01-25 |
Pfizer Inc. |
Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
|
|
CA2701710C
(en)
|
2004-07-20 |
2013-08-27 |
Warner-Lambert Company Llc |
Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
|
AU2005298383A1
(en)
*
|
2004-10-28 |
2006-05-04 |
Warner-Lambert Company Llc |
Process for forming amorphous atorvastatin
|
|
US20090088465A1
(en)
*
|
2004-12-02 |
2009-04-02 |
Stephen Craig Dyar |
Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
|
|
US7714141B2
(en)
*
|
2005-05-31 |
2010-05-11 |
Kowa Co., Ltd. |
Processes for production of optically active PPAR-activating compounds and intermediates for production thereof
|
|
CA2547216A1
(en)
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
|
ATE466840T1
(de)
|
2005-11-21 |
2010-05-15 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
|
|
US20110165641A1
(en)
*
|
2006-03-31 |
2011-07-07 |
The Board Of Trustees Of Michigan State University |
Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
|
|
KR20090039738A
(ko)
*
|
2006-07-19 |
2009-04-22 |
보드 오브 트러스티즈 오브 미시건 스테이트 유니버시티 |
Ｄ－１，２，４－부탄트리올의 미생물 합성
|
|
KR100850558B1
(ko)
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
|
JP2009256316A
(ja)
|
2008-03-28 |
2009-11-05 |
Daicel Chem Ind Ltd |
β−ヒドロキシ−γ−ブチロラクトンの製造方法
|
|
CN101337906B
(zh)
*
|
2008-08-15 |
2012-06-27 |
河南豫辰精细化工有限公司 |
一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
|
|
WO2010069593A1
(en)
|
2008-12-19 |
2010-06-24 |
Krka, D. D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2327682A1
(en)
|
2009-10-29 |
2011-06-01 |
KRKA, D.D., Novo Mesto |
Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
|
|
EP2726456A1
(en)
|
2011-07-01 |
2014-05-07 |
DSM Sinochem Pharmaceuticals Netherlands B.V. |
Micronized crystals of atorvastatin hemicalcium
|
|
CN106397241A
(zh)
*
|
2016-08-23 |
2017-02-15 |
杨锋 |
一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
|
|
CN106588689A
(zh)
*
|
2016-12-15 |
2017-04-26 |
河南豫辰药业股份有限公司 |
一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
|
|
CN112939901B
(zh)
*
|
2021-02-09 |
2023-05-09 |
中国科学院福建物质结构研究所 |
一种α-羟基-γ-丁内酯的制备方法
|
|
CN114195670B
(zh)
*
|
2021-12-31 |
2024-03-15 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀母核m4的精制方法
|
|
CN117447350B
(zh)
*
|
2023-10-26 |
2026-02-13 |
河南豫辰药业股份有限公司 |
一种阿托伐他汀m4有机废物综合再利用方法
|